SynthesisFrontiers in medicine2025
Glomerular hyperfiltration defined by eGFR and long-term clinical outcomes: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glomerular hyperfiltration (GHF) has been widely recognized as a potential risk factor. However, current evidence regarding both its precise definition and clinical prognostic value remains inconclusive. Methods: We systematically searched PubMed, Embase, and the Cochrane Library, as well as reference lists of relevant articles. Cohort studies examining the association between eGFR-defined GHF and clinical outcomes were included, and meta-analyses were conducted using a random-effects model. Cross-sectional studies and data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate and compare the 95th percentile of eGFR in healthy populations in China and the United States. Results: The 95th percentile eGFR values among healthy individuals ranged from 94.7 to 146.7 mL/min/1.73 m Conclusion: Although eGFR is subject to measurement biases in non-CKD populations, extremely high values may still indicate underlying risks not captured by routine monitoring. This study provides reference values for the 95th percentile of eGFR in the general Chinese and American populations and underscores the need to validate individualized definitions of GHF. Given the limited and heterogeneous evidence base, these findings should be interpreted cautiously, and further prospective studies are needed to clarify the clinical significance of GHF. Systematic review registration: INPLASY 202540039.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.